期刊文献+

血清HE4与CA125联合检测在早期卵巢癌诊断中的应用价值探讨 被引量:4

Combined detection of serum HE4 and CA125 in diagnosis of early ovarian cancer
下载PDF
导出
摘要 目的 探讨人附睾蛋白4(human epididymis protein-4,HE4)与糖类抗原125(CA125)联合检测在早期卵巢癌诊断中的应用价值.方法 选取本院2014年8月至2015年5月收治的20例卵巢癌(甲组)、20例卵巢良性病变患者(乙组),选取同时期健康体检者40例作为对照组,对三组对象血清HE4与CA125水平进行测定.结果 甲组患者血清HE4为(483.13±26.98) pmol/L,明显高于对照组和乙组,P< 0.05;甲组CA125为(345.81±40.34) pmol/L,显著高于对照组和乙组(P<0.05);HE4联合CA125检测敏感性高于两者单独检测,特异性高于CA125单独检测,低于HE4单独检测(P<0.05).结论 血清HE4与CA125联合检测早期卵巢癌价值优于两者单独检测,可明显提高诊断敏感性,为疾病的诊断、治疗提供专业参考,值得临床推广应用. Objective To investigate the application value of human epididymis protein 4 (epididymis protein-4 human,HE4) and carbohydrate antigen 125 (CA125) in the diagnosis of early ovarian cancer.Methods 20 patients with ovarian cancer (group A) and 20 patients with benign ovarian lesions (group B) treated at our hospital from August,2014 to May,2015 were selected.40 healthy subjects taking physical examination during the same period were selected as a control group.The serum levels of HE4 and CA125 of these three groups were measured.Results The serum levels of HE4 and CA125 was (483.13±26.98) pmol/L and (345.81±40.34)pmol/L in group A,which were significantly higher than those in the control group and group B (P〈0.05).The detection sensitivity of the combination of HE4 CA125 was higher than that of either HE4 or CA125.The specificity of the combination of HE4 CA125 was higher than that of CA125 and lower than that of HE4(P〈0.05).Conclusions The value of the combined detection of serum HE4 and CA125 in the diagnosis of early ovarian cancer is better than that of either one and can significantly improve the diagnostic sensitivity and provide professional reference for the diagnosis of the disease,so it is worth being clinically generalized.
出处 《国际医药卫生导报》 2016年第14期2167-2169,共3页 International Medicine and Health Guidance News
关键词 卵巢癌 HE4 CA125 诊断 Ovarian carcinoma Diagnosis Ovarian carcinoma Diagnosis
  • 相关文献

参考文献6

二级参考文献43

  • 1Mann DV, Edwards R, Ho S, et al.Elevated tumor marker CA 199:Clinical interpretation and influence of obstructive jaundice[J].Eur J Surg Ocol, 2000, 26: 474-479.
  • 2Moss El, Hollingworth J.The role of CA125 in clinical practice [J]. Clin Pathol, 2005, 58 ( 3 ):308-312.
  • 3Norum LF, Erikstein B, Nustad K.Elevated CA125 in breastCancer-A Sign of advanced disease[J]. Tumour Biol, 2001, 22 (4):223-228.
  • 4Ishigami S, Natsugoe S, Hokita S, et al.Clinieal importance of preopretive eareinoembryonie antigen and carbohydrate antigen 199 levels in gastrie eaneer[J].J Clin Gastro, 2001, 32 ( 1 ):41-44.
  • 5Riedinger J, Bonnetain F, Basuyau J, et al. Change in CA125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome [J]. Ann Oncol, 2007,18(5) :881-885.
  • 6Huhtinen K, Suvitie P, Hiissa J. Serum HE4 concentration differentiates malignant ovarian tumors from ovarian endometriotic cysts [J]. Br J Cancer, 2009,100(7):1315-1319.
  • 7Barbieri R L. In women who have a pelvic mass Have you tried this new ovarian Ca biomarker? [J]. OBG Management, 2010,22(4) : 8-12.
  • 8Trape J, Olaguer J P, Buxo J, et al. Biological variation of tumor markers and its application in the detection of disease progression in patients with non-small cell lung cancer [J]. Clin Chem, 2005,51 ( 1 ) : 220-222.
  • 9Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of muhimodal and ultrasound screening for ovarian cancer,and stage distribution of detected cancers results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening(UKCTOCS) [J]. Lancet Oneol, 2009,10(4) : 327-340.
  • 10Moore R G, Brown A K, Miller M C, et al. The use of multip le novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass [J]. Gynecol Oncol, 2008,108(2) :405.

共引文献112

同被引文献32

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部